News
ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma
- Author:
- Andrew D. Bowser
A 74% complete response rate is encouraging in interim analysis of the phase 2 study, but requires further...
News
Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL
- Author:
- Andrew D. Bowser
Durable responses were seen among patients with follicular lymphoma and diffuse large B-cell lymphoma, an...
News
Duvelisib response rate encouraging in phase 2 PRIMO trial of patients with r/r PTCL
- Author:
- Andrew D. Bowser
Toxicities were manageable in the ongoing dose-expansion phase, which is expected to complete enrollment in...
News
Allogeneic transplant leads to durable remissions in T-cell lymphomas
- Author:
- Andrew D. Bowser
Retrospective study demonstrates overall survival over 50% at 5 years, though transplant-related mortality and graft-versus-host disease need to...
News
ZUMA-5: Axi-cel yields high response rate in indolent NHL
- Author:
- Andrew D. Bowser
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
News
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry
- Author:
- Andrew D. Bowser
Preliminary data support “emerging consensus” of substantial morbidity and mortality but do not support...
Article
ASCO advises against PARP inhibitor retreatment in ovarian cancer
- Author:
- Andrew D. Bowser
ASCO guidelines detail recommendations for PARP inhibitor treatment in ovarian cancer.
News
OSA diagnoses not carried forward to the inpatient setting
- Author:
- Andrew D. Bowser
Missed OSA diagnoses could have especially negative implications for patients who don’t continue on positive airway pressure (PAP) therapy during...
News
Switching to riociguat effective for some patients with PAH not at treatment goal
- Author:
- Andrew D. Bowser
The clinical benefit of the switching to the sGC inhibitor was consistent across patient subgroups in the phase 4 REPLACE study.
News

Certain statins linked to lower mortality risk in patients admitted for sepsis
- Author:
- Andrew D. Bowser
Statin use was associated with lower mortality, compared with no use, with hydrophilic and synthetic statins besting lipophilic and fungal-derived...
News

COVID-19 experience forced residents to quickly improve patient communication skills
- Author:
- Andrew D. Bowser
At the peak of the pandemic in New York City, goals of care discussions became easier, though coping with death remains an issue.
News

National lung cancer screening guidelines may miss younger African American individuals at high risk
- Author:
- Andrew D. Bowser
Retrospective analysis finds many lung cancer patients would not have counted as eligible for low-dose CT under guidelines that are being...
News

Fauci: Cautious optimism for COVID-19 vaccine by end of 2020
- Author:
- Andrew D. Bowser
Top health official is “cautiously optimistic” for vaccine distribution before end of year, pending favorable safety and efficacy data.
News
COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate
- Author:
- Andrew D. Bowser
No increase was seen in hospitalization and death rates, providing additional support for keeping patients on these immunosuppressive treatments...
News
ctDNA clearance tracks with PFS in NSCLC subtype
- Author:
- Andrew D. Bowser
The median progression-free survival was significantly longer for patients with circulating tumor DNA clearance.